CON Stock Analysis: Concentra Holdings Parent | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 4.074m USD | 12M Return: 56% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.1M
Qual. Beats: 3
Rev. Trend: 94.6%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 1.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Concentra Group Holdings Parent, Inc. (CON) is a U.S. provider of occupational health services organized into three segments: Occupational Health centers, Onsite health clinics, and Other business. Founded in 1979 and headquartered in Addison, Texas, the company delivers a broad service mix spanning workers compensation care, employer and consumer health offerings, employer-sponsored primary care at the workplace, urgent care, injury care, preventive care, drug and alcohol screenings, vaccinations, physical examinations, and clinical testing.
Alongside its physical clinics, Concentra operates several specialized units: Concentra Telemed, a telemedicine platform for work-related injuries and illnesses; Concentra Pharmacy, which distributes repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps employers manage regulated and non-regulated drug and alcohol testing programs. The company is classified within the GICS Health Care Services sub-industry, a sector that typically generates revenue by providing outsourced clinical and administrative services to employers, payers, and patients rather than through traditional hospital or insurance channels. Concentra began trading on the NYSE on July 25, 2024.
- Workers comp claim volume tracks US employment and labor market strength
- Onsite clinic segment expansion drives same-center revenue growth
- Telemedicine adoption and pricing power expand occupational health margins
| Net Income: 178.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.60 > 1.0 |
| NWC/Revenue: 3.73% < 20% (prev 1.61%; Δ 2.12% < -1%) |
| CFO/TA 0.10 > 3% & CFO 288.7m > Net Income 178.0m |
| Net Debt (2.61b) to EBITDA (430.5m): 6.06 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.2m) vs 12m ago 1.20% < -2% |
| Gross Margin: 27.79% > 18% (prev 28.94%; Δ -1.15% > 0.5%) |
| Asset Turnover: 79.45% > 50% (prev 70.84%; Δ 8.62% > 0%) |
| Interest Coverage Ratio: 3.20 > 6 (EBIT TTM 351.6m / Interest Expense TTM 109.9m) |
| A: 0.03 (Total Current Assets 404.2m - Total Current Liabilities 320.9m) / Total Assets 2.89b |
| B: 0.06 (Retained Earnings 186.8m / Total Assets 2.89b) |
| C: 0.13 (EBIT TTM 351.6m / Avg Total Assets 2.81b) |
| D: 0.17 (Book Value of Equity 424.7m / Total Liabilities 2.44b) |
| Altman-Z'' = 1.42 = BB |
| DSRI: 0.99 (Receivables 296.5m/258.1m, Revenue 2.23b/1.93b) |
| GMI: 1.04 (GM 28.94% / 27.79%) |
| AQI: 0.97 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.15 (Revenue 2.23b / 1.93b) |
| TATA: -0.04 (NI 178.0m - CFO 288.7m) / TA 2.89b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 31.55 with a total of 589,756 shares traded. Over the past week, the price has changed by -1.13%, over one month by +18.56%, over three months by +44.22% and over the past year by +55.99%.
Current recommended Stop Loss: 30.50 (which is 3.3% or 1.4 ATR below the current price).
Concentra Holdings Parent has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CON.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.5 | -0.2% |
P/E Trailing = 22.9065
P/E Forward = 21.1416
P/S = 1.8252
P/B = 9.6142
Revenue TTM = 2.23b USD
EBIT TTM = 351.6m USD
EBITDA TTM = 430.5m USD
Long Term Debt = 1.56b USD (from longTermDebt, last quarter)
Short Term Debt = 98.9m USD (from shortTermDebt, last quarter)
Debt = 2.67b USD (from shortLongTermDebtTotal, last quarter) + Leases 546.5m
Net Debt = 2.61b USD (calculated: Debt 2.67b - CCE 61.7m)
Enterprise Value = 6.68b USD (4.07b + Debt 2.67b - CCE 61.7m)
Interest Coverage Ratio = 3.20 (Ebit TTM 351.6m / Interest Expense TTM 109.9m)
EV/FCF = 22.78x (Enterprise Value 6.68b / FCF TTM 293.4m)
FCF Yield = 4.39% (FCF TTM 293.4m / Enterprise Value 6.68b)
FCF Margin = 13.14% (FCF TTM 293.4m / Revenue TTM 2.23b)
Net Margin = 7.97% (Net Income TTM 178.0m / Revenue TTM 2.23b)
Gross Margin = 27.79% ((Revenue TTM 2.23b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 26.48% (prev 26.11%)
Tobins Q-Ratio = 2.31 (Enterprise Value 6.68b / Total Assets 2.89b)
Interest Expense / Debt = 4.12% (Interest Expense 109.9m / Debt 2.67b)
Taxrate = 22.98% (55.0m / 239.5m)
NOPAT = 270.8m (EBIT 351.6m * (1 - 22.98%))
Current Ratio = 1.26 (Total Current Assets 404.2m / Total Current Liabilities 320.9m)
Debt / Equity = 6.28 (Debt 2.67b / totalStockholderEquity, last quarter 424.7m)
Debt / EBITDA = 6.06 (Net Debt 2.61b / EBITDA 430.5m)
Debt / FCF = 8.89 (Net Debt 2.61b / FCF TTM 293.4m)
Total Stockholder Equity = 386.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.34% (Net Income 178.0m / Total Assets 2.89b)
RoE = 46.05% (Net Income TTM 178.0m / Total Stockholder Equity 386.5m)
RoCE = 18.04% (EBIT 351.6m / Capital Employed (Equity 386.5m + L.T.Debt 1.56b))
RoIC = 10.39% (NOPAT 270.8m / Invested Capital 2.61b)
WACC = 6.31% (E(4.07b)/V(6.74b) * Re(8.36%) + D(2.67b)/V(6.74b) * Rd(4.12%) * (1-Tc(0.23)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.50 | Cagr: 0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈247.6m ; Y1≈283.8m ; Y5≈417.7m
[DCF] Fair Price = 28.75 (EV 6.29b - Net Debt 2.61b = Equity 3.68b / Shares 128.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.38 | # QB: 3
Revenue Correlation: 94.62 | Revenue CAGR: 8.49% | SUE: 2.16 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.42 | Chg30d=-1.10% | Revisions=-25% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=-0.38% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=-0.09% | Revisions=+50% | GrowthEPS=+10.5% | GrowthRev=+7.9%
EPS next Year (2027-12-31): EPS=1.69 | Chg30d=-0.59% | Revisions=+67% | GrowthEPS=+11.6% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +53% (up=10, down=2)